Published 07:04 IST, August 21st 2020
Pfizer looking to make selection of COVID-19 vaccine for final trials
Pharmaceutical company Pfizer and its German partner have announced that they will choose the CVID-19 vaccine that exhibits the least number of symptoms
Advertisement
Pharmaceutical company Pfizer and its German partner have anunced that y will choose COVID-19 vaccine that exhibits least number of symptoms into final testing phase. According to Pfizer researcher two vaccine candidates that are favourite for selection have shown to strengn immune systems similarly, at same time do t have any serious side effects.
Will choose vaccine with fewest side effects
Despite lack of severe symptoms in both possible vaccine candidates, one seemingly caused considerably fewer injection reactions like mild fever, heache, chills or muscle pain, especially in older ults. Final testing or pharmaceutical company’s le vaccine candidate has begun and researchers have started recruiting thousands of volunteers from US and or countries. This will be one of a hand-full of COVID-19 vaccines to reach final st of testing.
Advertisement
Advertisement
Russia to test 'Sputnik V' vaccine
Russia is currently preparing to test its 'Sputnik V' vaccine on as many as 40,000 people next week. testing will be done across nation and will be monitored by a foreign research body, said backers of project on Thursday, August 20. Russia caused a stir in international community by being first country in world to anunce that it h discovered vaccine for COVID-19.
Given lack of data surrounding potential vaccine, international community and experts have expressed ir doubts. Countries like Iran have stated that y will wait for vaccine to get approval from World Health Organization before starting negotiations toward purchasing vaccine.
Advertisement
Russia’s vaccine candidate is named ‘Sputnik V’ in hom to world’s first satellite developed by Soviet Union. Russian President Vlimir Putin mentioned that one of his two ult daughters has been iculated. authorities from nation hailed efficiency of its COVID-19 vaccine after a two-month-long small-scale human trial, details of which, however, are t been me available to public.
(Im Credit AP) (Representative Im) (with ncy inputs)
Advertisement
Advertisement
07:04 IST, August 21st 2020